Citigroup’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-127,437
| Closed | -$2.57M | – | 6220 |
|
|
2021
Q3 | $2.57M | Sell |
127,437
-14,431
| -10% | -$398K | ﹤0.01% | 2335 |
|
|
2021
Q2 | $5.29M | Sell |
141,868
-25,471
| -15% | -$781K | ﹤0.01% | 1845 |
|
|
2021
Q1 | $4.28M | Buy |
167,339
+142,627
| +577% | +$3.64M | ﹤0.01% | 1890 |
|
|
2020
Q4 | $544K | Buy |
24,712
+16,018
| +184% | +$353K | ﹤0.01% | 4132 |
|
|
2020
Q3 | $156K | Sell |
8,694
-249,464
| -97% | -$5.17M | ﹤0.01% | 4791 |
|
|
2020
Q2 | $6.56M | Buy |
258,158
+219,870
| +574% | +$4.74M | 0.01% | 1634 |
|
|
2020
Q1 | $704K | Buy |
38,288
+22,311
| +140% | +$434K | ﹤0.01% | 3540 |
|
|
2019
Q4 | $352K | Sell |
15,977
-40,449
| -72% | -$814K | ﹤0.01% | 4727 |
|
|
2019
Q3 | $810K | Sell |
56,426
-391
| -0.7% | -$5.59K | ﹤0.01% | 3870 |
|
|
2019
Q2 | $895K | Buy |
56,817
+43,536
| +328% | +$592K | ﹤0.01% | 3764 |
|
|
2019
Q1 | $195K | Sell |
13,281
-153,768
| -92% | -$1.77M | ﹤0.01% | 5127 |
|
|
2018
Q4 | $1.79M | Buy |
167,049
+154,352
| +1,216% | +$2.03M | ﹤0.01% | 2776 |
|
|
2018
Q3 | $193K | Sell |
12,697
-61,575
| -83% | -$896K | ﹤0.01% | 5297 |
|
|
2018
Q2 | $910K | Buy |
+74,272
| New | +$933K | ﹤0.01% | 3459 |
|
|
2017
Q2 | – | Sell |
-1,097
| Closed | -$4K | – | 7558 |
|
|
2017
Q1 | $4K | Hold |
1,097
| – | – | ﹤0.01% | 6881 |
|
|
2016
Q4 | $3K | Sell |
1,097
-3,347
| -75% | -$11.9K | ﹤0.01% | 7034 |
|
|
2016
Q3 | $26K | Buy |
4,444
+875
| +25% | +$3.07K | ﹤0.01% | 6081 |
|
|
2016
Q2 | $10K | Sell |
3,569
-14,596
| -80% | -$59.9K | ﹤0.01% | 6565 |
|
|
2016
Q1 | $97K | Buy |
18,165
+12,831
| +241% | +$81K | ﹤0.01% | 5685 |
|
|
2015
Q4 | $63K | Buy |
5,334
+4,332
| +432% | +$49.6K | ﹤0.01% | 5760 |
|
|
2015
Q3 | $8K | Sell |
1,002
-399
| -28% | -$4.61K | ﹤0.01% | 6569 |
|
|
2015
Q2 | $20K | Buy |
1,401
+967
| +223% | +$17.7K | ﹤0.01% | 6110 |
|
|
2015
Q1 | $11K | Sell |
434
-3,158
| -88% | -$71K | ﹤0.01% | 6437 |
|
|
2014
Q4 | $59K | Buy |
3,592
+2,449
| +214% | +$28.3K | ﹤0.01% | 5587 |
|
|
2014
Q3 | $14K | Buy |
1,143
+1,017
| +807% | +$15.3K | ﹤0.01% | 6109 |
|
|
2014
Q2 | $3K | Buy |
+126
| New | +$2.29K | ﹤0.01% | 6666 |
|
Other funds holding DRNA
Citigroup's DRNA Position: Q4 2021 in Review
Citigroup sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 127,437 shares — an estimated $2.57M sold.
Citigroup first reported a position in DRNA in Q2 2014 and held it in 26 quarters. The position peaked at $6.56M in Q2 2020. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.
- Citigroup reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
- Citigroup sold 127,437 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $2.57M.
- Citigroup first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2014 and held it in 26 quarters.
- Citigroup's Dicerna Pharmaceuticals, Inc. position peaked at $6.56M in Q2 2020.
- 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.
Based on Citigroup's 13F filing for Q4 2021, filed 10 Feb 2022.